eTheRNA immunotherapies is a clinical-stage Belgian biotech company applying mRNA based immunotherapies to the treatment of cancer and infectious diseases. eTheRNA’s goal is to commercialize these immunotherapies to deliver long lasting clinical remission to cancer patients.
eTheRNA was established in January 2013 as a spin-off company of the ‘Vrije Universiteit Brussel’ (VUB), following the development of the TriMix technology. In July of 2015, eTheRNA obtained from the VUB a worldwide exclusive license on the TriMix technology.
In March 2016, eTheRNA immunotherapies secured EUR 24 million in a Series A investment with a strong international syndicate of investors. This enables the company to continue the development of mRNA-based immunotherapies for with clinical studies in Melanoma and Breast cancer.
In 2017, eTheRNA relocated to Niel, near Antwerp, Belgium, where a cGMP-compliant mRNA manufacturing laboratory was inaugurated in October 2018.
Our strategy entails the development and commercialization of a range of multi-modal products based on TriMix or a similar mRNA technology.
- Broad application in major cancer types (lung metastasis, colorectal cancer, breast cancer) of a combined vaccine and local tumor treatment combination in synergy with standard of care. This product range will be partnered with a major pharma player.
- Selected application in orphan cancer types (Melanoma, Glioblastoma, pediatric tumors) or patient settings (patients with autoimmune deficiencies, elderly patients, personalized medicine) of a combined vaccine and local tumor treatment combination. This product range will be developed and marketed by eTheRNA.
- Personalized medicine based on ex-vivo stimulation of dendritic cells aimed towards selected oncology indications. This product range will be developed and commercialized in collaboration with partners.